EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS

EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS

The purpose of the study was to analyze the ability of five antitumor drugs from the pharmaceutical group of protein kinase inhibitors (gefitinib, imatinib, pazopanib, ponatinib and enzastaurin) to reactivate the expression of the epigenetically silenced GFP in HeLa TI cells, and to estimate the eff...

Full description

Bibliographic Details
Main Authors: V. P. Maksimova, J. V. Makus, O. G. Usalka, E. S. Lylova, P. E. Bugaeva, E. M. Zhidkova, D. A. Fedorov, O. P. Lizogub, E. A. Lesovaya, G. A. Belitsky, M. G. Yakubovskaya, K. I. Kirsanov
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2020-09-01
Series:Сибирский онкологический журнал
Subjects:
protein kinase inhibitors
enzastaurin
epigenetic activity
hela ti
histone modifications
dna methylation
hat
hdac
Online Access:https://www.siboncoj.ru/jour/article/view/1531

Internet

https://www.siboncoj.ru/jour/article/view/1531

Similar Items